A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.

Elizabeth R Kessler Eryn Callihan Junxiao Hu Corbin J Eule Geetika Srivastava Douglas J Kemme Praveena Iruku Vishal Rana James Moore Steven R Schuster Mali Amirault Thomas W Flaig Elaine T Lam

Published in: Cancer research communications (2023)

This study evaluated the safety and effectiveness of the combination of pembrolizumab and cabozantinib in patients with mRCC. The safety profile was manageable. The combination showed promising activity with an objective response rate of 65.8%, median PFS of 10.45 months, and median OS of 30.81 months.

Keyphrases

metastatic renal cell carcinoma
clinical trial
advanced non small cell lung cancer
randomized controlled trial
study protocol
open label
phase iii